Blue Owl Capital Corporation announced it will report its financial results for the third quarter ending September 30, 2026, on November 4 after market close. The company will host a webcast and conference call on November 5 at 10:00 a.m. Eastern Time to discuss the results. Blue Owl Capital focuses on lending to U.S. middle-market companies and manages a portfolio valued at $15 billion as of mid-2026. This earnings release provides investors insight into the company's recent performance and outlook.
Blue Owl Capital Corporation's upcoming earnings release and call provide context for financial sector activity. For readers following Financials-sector stocks on Pluang, here is the market snapshot as of Oct 02, 2026 02:31 WIB: Of 85 priced US Financials stocks, 36 rose and 48 fell today. Notable movers include AEG (Aegon Ltd.) at USD 8.44 with a 1-day change of -2.20% and 100% buy order activity, C (Citigroup Inc.) at USD 126.77 with a -2.13% change and 58% buy orders, and ACT (Enact Holdings Inc) at USD 44.15 with a +2.06% change and balanced buy/sell activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
